Drug delivery from internally implanted biomedical devices used in traumatology and in orthopedic surgery

Expert Opinion on Drug Delivery

Volumn 7, Issue 5, 2010, Pages 589-603

  Arruebo, Manuel ^a,b   Vilaboa, Nuria ^b,c   Santamaria, Jesus ^a,b  

^a Instituto de Ciencia de Materiales de Aragón   (Spain)

^b BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

Author keywords

Antibiotic; Biomaterials; Biomedical devices; Drug delivery; Implants; Orthopedic surgery; Traumatology

Indexed keywords

ANTIINFECTIVE AGENT; AZTREONAM; BIOMATERIAL; BIOPOLYMER; BONE CEMENT; CARMUSTINE; CIPROFLOXACIN; DUOCID; GENTAMICIN; GROWTH FACTOR; HISTRELIN; HORMONE; LEUPRORELIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULPERAZON; TETRACYCLINE; TOBRAMYCIN; VANCOMYCIN; DELAYED RELEASE FORMULATION;

ALZHEIMER DISEASE; BIOMECHANICS; BONE REMODELING; COST MINIMIZATION ANALYSIS; DEVICE; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; DRUG RELEASE; ENDOMETRIOSIS; GYNECOLOGIC DISEASE; HUMAN; IMPLANT; MEDICAL INSTRUMENTATION; ORTHOPEDIC SURGERY; OSTEOMYELITIS; PATIENT SAFETY; PERIODONTAL DISEASE; PRECOCIOUS PUBERTY; PROSTATE CANCER; PROSTHESIS; REVIEW; RISK BENEFIT ANALYSIS; SCANNING ELECTRON MICROSCOPY; SURFACE PROPERTY; THERMODYNAMICS; TRAUMATOLOGY; ANIMAL; DELAYED RELEASE FORMULATION; ORTHOPEDICS; PROCEDURES; PROSTHESES AND ORTHOSES;

ANIMALS; DELAYED-ACTION PREPARATIONS; HUMANS; ORTHOPEDICS; PROSTHESES AND IMPLANTS; TRAUMATOLOGY;

EID: 77951491570     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425241003671544     Document Type: Review

References (97)

1. Available from: http://www.fda.gov/ CombinationProducts/ [Last accessed 12 Dec 2009]
2. Adams SB, Shamji MF, Nettles DL, et al. Sustained release of antibiotics from injectable and thermally responsive polypeptide depots. J Biomed Mater Res B Appl Biomater 2009;90B:67-74
3. Jiang B, Li B. Tunable drug loading and release from polypeptide multilayer nanofilms. Int J Nanomed 2009;4:37-53
4. Jiang B, Li B. Polypeptide nanocoatings for preventing dental and orthopaedic device-associated infection: pH-induced antibiotic capture, release, and antibiotic efficacy. J Biomed Mater Res B Appl Biomater 2009;88:332-338
5. Yamashita Y, Uchida A, Yamakawa T, et al. Treatment of chronic osteomyelitis using calcium hydroxyapatite ceramic implants impregnated with antibiotic. Int Orthop 1998;22:247-251
6. Khang G, Choi HS, Rhee JM, et al. Controlled release of gentamicin sulfate from poly (3-hydroxybutyrate-co-3-hydroxyvalerate) wafers for the treatment of osteomyelitis. Korea Polym J 2000;8:253-260
7. Iyer SS, Barr WH, Karnes HT. Profiling in vitro drug release from subcutaneous implants: a review of current status and potential implications on drug product development. Biopharm Drug Dispos 2006;27:157-170
8. American Academy of Orthopedic Surgeons. Information about Orthopedic Patients and Conditions. Available from: http://www.aaos.org/ Research/stats/patientstats.asp. [Accessed 9 September 2009]
9. Antoci V, King SB, Jose B, et al. Vancomycin covalently bonded to titanium alloy prevents bacterial colonization. J Orthop Res 2007;25:858-866
10. Shirtliff ME, Mader JT. Acute septic arthritis. Clin Microbiol Rev 2002;15:527-544
11. Cuckler JM, Star AM, Alavi A, et al. Diagnosis and management of the infected total joint arthroplasty. Orthop Clin North Am 1991;22:523-530
12. Hanssen AD, Rand JA. Evaluation and treatment of infection at the site of a total hip or knee arthroplasty. J Bone Joint Surg Am 1998;80:910-922
13. Moellering RC Jr. Vancomycin: a 50-year reassessment. Clin Infect Dis 2006;42:S3-4
14. Soundrapandian C, Datta S, Sa B. Drug-eluting implants for osteomyelitis. Crit Rev Ther Drug Carrier Syst 2007;24:493-545
15. Elek SD, Conen PE. The virulence of Staphylococcus pyogenes for man. A study of the problems of wound infection. Br J Exp Pathol 1957;38:573-586
16. An YH, Friedman RJ. Concise review of mechanisms of bacterial adhesion to biomaterial surfaces. J Biomed Mater Res 1998;43:338-348
17. Diefenbeck M, Mückler T, Hofmann GO. Prophylaxis and treatment of implant-related infections by local application of antibiotics. Injury 2006;37:S95-104
18. Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet 2001;358:135-138
19. Donlan RM. Biofilms and device-associated infections. Emerg Infect Dis J 2001;7:277-281
20. Charnley J. Fracture of femoral prostheses in total hip replacement. A clinical study. Clin Orthop Relat Res 1975;111:105-120
21. Harris WH, Schiller AL, Scholler JM, et al. Extensive localized bone resorption in the femur following total hip replacement. J Bone Joint Surg Am 1976;58:612-618
22. Purdue PE, Koulouvaris P, Potter HG, et al. The cellular and molecular biology of periprosthetic osteolysis. Clin Orthop Relat Res 2007;454:251-261
23. Ingham E, Fisher J. Biological reactions to wear debris in total joint replacement. Proc Inst Mech Eng 2000;214:21-37
24. Ulrich SD, Seyler TM, Bennett D, et al. Total hip arthroplasties: what are the reasons for revision? Int Orthop 2008;32:597-604
25. Mahomed NN, Barrett JA, Katz JN, et al. Rates and outcomes of primary and revision total hip replacement in the United States medicare population. J Bone Jnt Surg Am 2003;85A:27-32
26. Hanssen AD. Prophylactic use of antibiotic bone cement. An emerging standard--in opposition. J Arthropol 2004;19:73-77
27. Buchholz HW, Engelbrecht H. Depot effects of various antibiotics mixed with Palacos® resins. Chirurg 1970;41:511-515
28. Henry SL, Galloway KP. Local antibacterial therapy for the management of orthopedic infections. Pharmacokinetic considerations. Clin Pharmacokinet 1995;29:36-45
29. Passuti N, Gouin F. Antibiotic-loaded bone cement in orthopedic surgery. Joint Bone Spine 2003;70:169-174
30. Meyer JD, Falk RF, Kelly M, et al. Preparation and in vitro characterization of gentamycin-impregnated biodegradable beads suitable for treatment of osteomyelitis. J Pharma Sci 1998;87:1149-1154
31. Neut D, van de Belt H, van Horn JR, et al. Residual gentamicin-release from antibiotic-loaded polymethylmethacrylate beads after 5 years of implantation. Biomaterials 2003;24:1829-1831
32. Boesel LF, Azevedo HS, Reis RL. Incorporation of a-amylase enzyme and a bioactive filler into hydrophilic, partially degradable and bioactive cements (HDBCs) as a new approach to tailor their simultaneous degradation and bioactive behaviour. Biomacromol 2006;7:2600-2609
33. Kulkarni RK, Pani KC, Neuman C, et al. Polylactic acid for surgical implants. Arch Surg 1966;93:839-843
34. Mendel V, Simanowski HJ, Scholz HC, et al. Therapy with gentamicin-PMMA beads, gentamicin-collagen sponge, and cefazolin for experimental osteomyelitis due to Staphylococcus aureus in rats. Arch Orthop Trauma Surg 2005;125:363-368
35. Ruszczak Z, Friess W. Collagen as a carrier for on-site delivery of antibacterial drugs. Adv Drug Deliv Rev 2003;55:1679-1698
36. Song E, Kim SY, Chun T, et al. Collagen scaffolds derived from a marine source and their biocompatibility. Biomaterials 2006;27:2951-2961
37. Yu D, Wong J, Matsuda Y, et al. Self-setting hydroxyapatite cement: a novel skeletal drug-delivery system for antibiotics. J Pharm Sci 1992;81:529-532
38. Nelson CL, McLaren SG, Skinner RA, et al. The treatment of experimental osteomyelitis by surgical debridement and the implantation of calcium sulfate tobramycin pellets. J Orthop Res 2002;20:643-647
39. Wang S. Ordered mesoporous materials for drug delivery. Microp Mesop Mater 2009;117(1-2):1-9
40. Jose B, Antoci V, Zeiger AR, et al. Vancomycin covalently bonded to titanium beads kills Staphylococcus aureus. Chem Biol 2005;12:1041-1048
41. Price JS, Tencer AF, Arm DM, et al. Controlled release of antibiotics from coated orthopedic implants. J Biomed Mater Res 1996;30:281-286
42. Darouiche RO, Farmer J, Chaput C, et al. Anti-infective efficacy of antiseptic-coated intramedullary nail. J Bone Joint Surg Am 1998;80:1336-1340
43. Raschke MJ, Schmidmaier G. Biological coating of implants in trauma and orthopedic surgery. Unfallchirurg 2004;107:653-663 (Pubitemid 39237166)
44. Darouiche RO, Mansouri MD, Zakarevicz D, et al. In vivo efficacy of antimicrobial-coated devices. J Bone Joint Surg 2007;89:792-797
45. Lucke M, Schmidmaier G, Sadoni S, et al. Gentamicin coating of metallic implants reduces implant-related osteomyelitis in rats. Bone 2003;32:521-531
46. Brett DW. A discussion of silver as an antimicrobial agent: alleviating the confusion. Ostomy Wound Manage 2006;52:34-41
47. Chen X, Schluesener HJ. Nanosilver: a nanoproduct in medical application. Toxicol Lett 2008;176:1-12
48. Rai M, Yadav A, Gade A. Silver nanoparticles as a new generation of antimicrobials. Biotechnol Adv 2009;27:76-83
49. Percival SL, Bowler PG, Russell D. Bacterial resistance to silver in wound care. J Hosp Infect 2005;60:1-7
50. Kaelicke T, Schierholz J, Schlegel U, et al. Effect on infection resistance of a local antiseptic and antibiotic coating on osteosynthesis implants: an in vitro and in vivo study. J Orthop Res 2006;24:1622-1640
51. Boyne PJ, Lilly LC, Marx RE, et al. De novo bone induction by recombinant human bone morphogenetic protein-2 (rhBMP-2) in maxillary sinus floor augmentation. J Oral Maxillofac Surg 2005;63:1693-1707
52. Boden SD, Zdeblick TA, Sandhu HS, et al. The use of rhBMP-2 in interbody fusion cages. Definitive evidence of osteoinduction in humans: a preliminary report. Spine 2000;25:376-381
53. Soballe K, Jensen TB, Mouzin O, et al. Differential effect of a bone morphogenetic protein-7 (OP-1) on primary and revision loaded, stable implants with allograft. J Biomed Mater Res A 2004;71:569-576
54. Sumner DR, Turner TM, Urban RM, et al. Additive enhancement of implant fixation following combined treatment with rhTGF-beta 2 and rhBMP-2 in a canine model. J Bone Joint Surg Am 2006;88A:806-817
55. Guicheux J, Gauthier O, Aguado E, et al. Human growth hormone locally released in bone sites by calcium-phosphate biomaterial stimulates ceramic bone substitution without systemic effects: a rabbit study. J Bone Mineral Res 1998;13:739-748
56. Di Silvio L, Bonfield W. Biodegradable drug delivery system for the treatment of bone infection and repair. J Mater Sci Mater Med 1999;10:653-658
57. Itokazu M, Kumazawa S, Wada E, et al. Sustained release of adriamycin from implanted hydroxyapatite blocks for the treatment of experimental osteogenic sarcoma in mice. Cancer Let 1996;107:11-18
58. Prokopowicz M. Correlation between physicochemical properties of doxorubicin-loaded silica/polydimethylsiloxane xerogel and in vitro release of drug. Acta Biomater 2009;5:193-207
59. Yoon JJ, Kim JH, Park TG. Dexamethasone-releasing biodegradable polymer scaffolds fabricated by a gas-foaming/salt-leaching method. Biomaterials 2003;24:2323-2329
60. Reno F, Cannas M. UHMWPE and vitamin E bioactivity: an emerging perspective. Biomaterials 2006;27:3039-3043
61. Govender S, Csimma C, Genant HK, et al. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am 2002;84:2123-2134
62. Vaccaro AR, Whang PG, Patel T, et al. The safety and efficacy of OP-1 (rhBMP-7) as a replacement for iliac crest autograft for posterolateral lumbar arthrodesis: minimum 4-year follow-up of a pilot study. Spine J 2007;8:457-465
63. Wysocki RW, Cohen MS. Ectopic ossification of the triceps muscle after application of bone morphogenetic protein-7 to the distal humerus for recalcitrant nonunion: a case report. J Hand Surg Am 2007;32:647-650
64. Axelrad TW, Steen B, Lowenberg DW, et al. Heterotopic ossification after the use of commercially available recombinant human bone morphogenetic proteins in four patients. J Bone Joint Surg Br 2008;90:1617-1622
65. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus and paclitaxel-eluting coronary stents. N Engl J Med 2007;356:998-1008
66. Elman NM, Patta Y, Scott AW, et al. The next generation of drug-delivery microdevices. Clin Pharm Ther 2009;85:544-547
67. Iqbal Z, Wang Y. Biofuel cell system for use as implantable device, e.g. pacemaker, includes first enzyme(s) immobilized with respect to first nanomaterial as anode, and second enzyme(s) immobilized with respect to second nanomaterial as cathode. US2008160384-A1
68. Sunagawa K, Sugimachi M, Inagaki M. Oxidase-based biological fuel cell-powered micro-integrated cardiac pacemakers for distributed cardiac pacing systems, applicable e.g. in brachycardic patients without needing lead and chest incision. WO2004012811-A1; AU2003252379-A1; EP1541191-A1
69. Kakehi N, Yamazaki T, Tsugawa W, et al. A novel wireless glucose sensor employing direct electron transfer principle based enzyme fuel cell. Biosens Bioelectron 2007;22:2250-2255
70. Brem S, Tyler B, Li K, et al. Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model. Cancer Chemother Pharmacol 2007;60:643-650
71. Martin F, Walczak R, Boiarski A, et al. Tailoring width of microfabricated nanochannels to solute size can be used to control diffusion kinetics. J Control Release 2005;102:123-133
72. Rebscher SJ, Hetherington AM, Snyder RL, et al. Design and fabrication of multichannel cochlear implants for animal research. J Neurosci Methods 2007;166:1-12
73. Lo R, Li PY, Saati S, et al. A refillable microfabricated drug delivery device for treatment of ocular diseases. Lab Chip 2008;8:1027-1030
74. Ciolino JB, Hoare TR, Iwata NG, et al. A drug-eluting contact lens. Invest Ophthalmol Vis Sci 2009;50:3346-3352
75. Xinming L, Yingde C, Lloyd AW, et al. Polymeric hydrogels for novel contact lens-based ophthalmic drug delivery systems. Cont Lens Anterior Eye 2008;31:57-64
76. Peterman MC, Bloom DM, Lee C, et al. Localized neurotransmitter release for use in a prototype retinal interface. Invest Ophthalmol Vis Sci 2003;44:3144-3149
77. Winter JO, Gokhale M, Jensen RJ, et al. Tissue engineering applied to the retinal prosthesis: Neurotrophin-eluting polymeric hydrogel coatings. Mater Sci Eng C 2008;28:448-453
78. In: Elsner P, Hatch K, Wigger-Alberti W, editors, Textiles and the skin. Curr Probl Dermatol Basel, Karger. 2003;31:82-97
79. Hayes PD, Nasim A, London NJM, et al. In situ replacement of infected aortic grafts with refampicin-bonded prostheses: the Leicester experience (1992 to 1998). J Vasc Surg 1999;30:92-98
80. Fortescue EB, Berul CI, Cecchin F, et al. Patient, procedural, and hardware factors associated with pacemaker lead failures in pediatrics and congenital heart disease. Heart Rhythm 2004;1:150-159
81. Sudo A, Hasegawa M, Fukuda A, et al. Treatment of Infected Hip Arthroplasty with Antibiotic-Impregnated Calcium Hydroxyapatite. J Arthroplasty 2008;23:145-150
82. Cai XZ, Yan SG, Wu HB, et al. Effect of delayed pulsed-wave ultrasound on local pharmacokinetics and pharmacodynamics of vancomycin-loaded acrylic bone cement in vivo. Antimicrob Agents Chemother 2007;51:3199-3204
83. Hsieh PH, Chang YH, Chen SH, et al. High concentration and bioactivity of vancomycin and aztreonam eluted from simplexTM cement spacers in two-stage revision of infected hip implants: a study of 46 patients at an average follow-up of 107 days. J Orthop Res 2006;24:1615-1621
84. Méndez JA, Abraham GA, Fernández MM, et al. Self-curing acrylic formulations containing PMMA/PCL composites: properties and antibiotic release behaviour. J Biomed Mater Res A 2002;61:66-74
85. Garvin KL, Miyano JA, Robinson D, et al. Polylactide/polyglycolide antibiotic implants in the treatment of osteomyelitis. A canine model. J Bone Joint Surg Am 1994;76:1500-1506
86. Ramchandani M, Robinson D. In vitro in vivo release of ciprofloxacin from PLGA 50:50 implants. J Control Release 1998;54:167-175
87. Castro C, Sánchez E, Delgado A, et al. Ciprofloxacin implants for bone infection. In vitro--in vivo characterization. J Control Release 2003;93:341-354
88. Stephens D, Li L, Robinson D, et al. Investigation of the in vitro release of gentamicin from a polyanhydride matrix. J Control Release 2000;63:305-317
89. Sancineto CF, Barla JD. Treatment of long bone osteomyelitis with a mechanically stable intramedullar antibiotic dispenser: nineteen consecutive cases with a minimum of 12 months follow-up. J Trauma Inj Infect Crit Care 2008;65:1416-1420
90. Englert C, Angele P, Fierlbeck J, et al. Conductive bone substitute material with variable antibiotic delivery. Unfallchirurg 2007;110:408-413
91. Beardmore AA, Brooks DE, Wenke JC, Thomas DB. Effectiveness of local antibiotic delivery with an osteoinductive and osteoconductive bone-graft substitute. J Bone Joint Surg Am 2005;87:107-112
92. Miyai T, Ito A, Tamazawa G, et al. Antibiotic-loaded poly-e-caprolactone and porous beta-tricalcium phosphate composite for treating osteomyelitis. Biomaterials 2008;29:350-358
93. Kanellakopoulou K, Galanopoulos I, Soranoglou V, et al. Treatment of experimental osteomyelitis caused by methicillin-resistant Staphylococcus aureus with a synthetic carrier of calcium sulphate (Stimulan®) releasing moxifloxacin. Int J Antimicrob Agents 2009;33:354-359
94. Leprêtre S, Chai F, Hornez JC, et al. Prolonged local antibiotics delivery from hydroxyapatite functionalised with cyclodextrin polymers. Biomaterials 2009;30:6086-6093
95. Kostamo T, Biring GS, Masri BA, et al. Two-stage hip revision for infection: A 10-15 year follow-up in 103 patients. Paper 349. Presented at the American Academy of Orthopedic Surgeons 75th Annual Meeting; March 5--9, 2008; San Francisco
96. Ueng SWN, Lee MS, Lin SS, et al. Development of a biodegradable alginate carrier system for antibiotics and bone cells. J Orthop Res 2007;25:62-72
97. Gürsel I, Korkusuz F, Türesin F, et al. In vivo application of biodegradable controlled antibiotic release systems for the treatment of implant-related osteomyelitis. Biomaterials 2001;22:73-80